CMN-005 by CoImmune for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

An artificial intelligence (AI) system was better at detecting clinically significant prostate cancer on MRI compared with radiologists, a noninferiority, confirmatory study showed. In a

June 14, 2024

Data needed to forge the link between AI and mRNA – Pharmaceutical Technology

Experts say that relevant datasets are essential to explore the use of AI in mRNA research. Image credit: Shutterstock / Gorodenkoff. Tackling two of the

June 6, 2024

Rising temperatures pose looming threat: Extreme heat could elevate cardiovascular mortality for US residents by midcentury

Researchers estimate the change in the severe heat-related cardiovascular mortality burden in the United States.

November 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.